Potent SARS-CoV2-specific T-cell response in asymptomatic hemodialysis patients with hidden COVID-19 infection history.
COVID-19
HLA-I-tetramer
SARS-CoV2
antibody
hemodialysis
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
24
01
2023
received:
29
08
2022
accepted:
04
03
2023
medline:
14
4
2023
pubmed:
22
3
2023
entrez:
21
3
2023
Statut:
ppublish
Résumé
COVID-19-related immune responses in patients with end-stage renal disease (ESRD) are characterized in detail by the humoral response, but their cellular immunity has not been clarified. Here, we evaluated virus-specific T cells in parallel with serology-related tests. In this study, 104 ESRD patients at the hemodialysis ward of Imam Reza hospital at Tabriz (Iran) were enrolled. After blood sampling, SARS-CoV2-specific humoral and cellular immune responses were evaluated by SARS-CoV2-specific IgM/IgG ELISA and peptide/MHCI-Tetramers flow cytometry, respectively. Our results showed that 14 (13.5%) and 45 (43.3%) patients had specific SARS-CoV2 IgM and IgG in their sera, respectively. Immunophenotyping for SARS-CoV2-specific CD8 Despite not having clinical symptoms, a high rate of SARS-CoV2-specific T-cell response in asymptomatic ESRD patients may reveal a high burden of asymptomatic COVID-19 infection in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
COVID-19-related immune responses in patients with end-stage renal disease (ESRD) are characterized in detail by the humoral response, but their cellular immunity has not been clarified. Here, we evaluated virus-specific T cells in parallel with serology-related tests.
METHODS
METHODS
In this study, 104 ESRD patients at the hemodialysis ward of Imam Reza hospital at Tabriz (Iran) were enrolled. After blood sampling, SARS-CoV2-specific humoral and cellular immune responses were evaluated by SARS-CoV2-specific IgM/IgG ELISA and peptide/MHCI-Tetramers flow cytometry, respectively.
RESULTS
RESULTS
Our results showed that 14 (13.5%) and 45 (43.3%) patients had specific SARS-CoV2 IgM and IgG in their sera, respectively. Immunophenotyping for SARS-CoV2-specific CD8
CONCLUSION
CONCLUSIONS
Despite not having clinical symptoms, a high rate of SARS-CoV2-specific T-cell response in asymptomatic ESRD patients may reveal a high burden of asymptomatic COVID-19 infection in these patients.
Identifiants
pubmed: 36941528
doi: 10.1002/jcla.24863
pmc: PMC10098065
doi:
Substances chimiques
RNA, Viral
0
Immunoglobulin G
0
Immunoglobulin M
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e24863Subventions
Organisme : Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
ID : 67507
Informations de copyright
© 2023 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
Gene Rep. 2021 Jun;23:101140
pubmed: 33869895
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
Cell. 2021 Apr 1;184(7):1671-1692
pubmed: 33743212
Clin Exp Immunol. 2020 Nov;202(2):193-209
pubmed: 32978971
Nat Med. 2021 Jan;27(1):78-85
pubmed: 33184509
J Clin Lab Anal. 2023 Mar;37(5):e24863
pubmed: 36941528
J Intern Med. 2021 Apr;289(4):559-573
pubmed: 33034095
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
Kidney Int. 2021 Jun;99(6):1470-1477
pubmed: 33774082
Cell Commun Signal. 2022 Aug 29;20(1):131
pubmed: 36038915
J Clin Invest. 2020 Dec 1;130(12):6477-6489
pubmed: 32833687
Gene Rep. 2022 Mar;26:101509
pubmed: 35071823
Immunol Invest. 2022 May;51(4):993-1004
pubmed: 33752550
Cell Commun Signal. 2022 Jul 16;20(1):106
pubmed: 35842705
IUBMB Life. 2021 Aug;73(8):1005-1015
pubmed: 34118117
Fam Pract. 2021 Mar 29;38(2):154-159
pubmed: 32914857
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Am J Transplant. 2021 Feb;21(2):854-863
pubmed: 33047493
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Anticancer Agents Med Chem. 2021 Oct 28;21(16):2142-2162
pubmed: 33563186
Iran J Basic Med Sci. 2017 Aug;20(8):940-943
pubmed: 29085586
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Mol Immunol. 2021 Oct;138:121-127
pubmed: 34392110
Nat Commun. 2021 Feb 17;12(1):1084
pubmed: 33597531